<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003143</url>
  </required_header>
  <id_info>
    <org_study_id>1607092776</org_study_id>
    <nct_id>NCT03003143</nct_id>
  </id_info>
  <brief_title>Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients</brief_title>
  <official_title>Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure frequency reduction</measure>
    <time_frame>3 month of vigabatrin administration</time_frame>
    <description>50% reduction - favorable outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>3 month of vigabatrin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Quality of Life in Epilepsy Inventory, QOLIE-31)</measure>
    <time_frame>after 3 month of vigabatrin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression (Beck Depression Inventory®-II)</measure>
    <time_frame>3 month of vigabatrin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition (Mini-Mental State Examination-Korean)</measure>
    <time_frame>3 month of vigabatrin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality (Pittsburgh Sleep Quality Assessment)</measure>
    <time_frame>3 month of vigabatrin administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Autoimmune Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Vigabatrin treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin 500 MG</intervention_name>
    <arm_group_label>Vigabatrin treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-85

          -  Possible autoimmune encephalitis

          -  Patients who have been diagnosed and treated for encephalitis for more than 4 weeks

          -  Patients with epilepsy (EEG finding or clinically)

        Exclusion Criteria:

          -  septic shock, fever &gt;38.5 ℃, O2 saturation &lt;90%, respiratory rate &gt;25, HR &gt;120

          -  previously, mRS=3 or mRS&gt;3

          -  MMSE&lt;20

          -  Patients who have terminal disease

          -  eye problem

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KON CHU, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KON CHU, MD, PhD</last_name>
    <phone>82-2-2072-3192</phone>
    <email>stemcell.snu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JIN-SUN JUN, MD</last_name>
    <phone>82-2-2072-3192</phone>
    <email>junjinsun0401@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kon Chu, Professor</last_name>
      <email>stemcell.snu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>JIN-SUN JUN, Fellow</last_name>
      <email>junjinsun0401@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kon Chu, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Bjurstöm H, Wang J, Ericsson I, Bengtsson M, Liu Y, Kumar-Mendu S, Issazadeh-Navikas S, Birnir B. GABA, a natural immunomodulator of T lymphocytes. J Neuroimmunol. 2008 Dec 15;205(1-2):44-50. doi: 10.1016/j.jneuroim.2008.08.017. Epub 2008 Oct 26. Erratum in: J Neuroimmunol. 2009 Sep 29;214(1-2):133. Wang, Junyang [corrected to Wang, JunYang].</citation>
    <PMID>18954912</PMID>
  </reference>
  <reference>
    <citation>Rossi S, Muzio L, De Chiara V, Grasselli G, Musella A, Musumeci G, Mandolesi G, De Ceglia R, Maida S, Biffi E, Pedrocchi A, Menegon A, Bernardi G, Furlan R, Martino G, Centonze D. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun. 2011 Jul;25(5):947-56. doi: 10.1016/j.bbi.2010.10.004. Epub 2010 Oct 20.</citation>
    <PMID>20940040</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kon Chu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vigabatrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

